Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Grazyna D. Szklarz is active.

Publication


Featured researches published by Grazyna D. Szklarz.


Journal of Computer-aided Molecular Design | 1997

Molecular modeling of cytochrome P450 3A4.

Grazyna D. Szklarz; James R. Halpert

The three-dimensional structure of human cytochrome P450 3A4 was modeled based on crystallographic coordinates of four bacterial P450s: P450 BM-3, P450cam, P450terp, and P450eryF. The P450 3A4 sequence was aligned to those of the known proteins using a structure-based alignment of P450 BM-3, P450cam, P450terp, and P450eryF. The coordinates of the model were then calculated using a consensus strategy, and the final structure was optimized in the presence of water. The P450 3A4 model resembles P450 BM-3 the most, but the B′ helix is similar to that of P450eryF, which leads to an enlarged active site when compared with P450 BM-3, P450cam, and P450terp. The 3A4 residues equivalent to known substrate contact residues of the bacterial proteins and key residues of rat P450 2B1 are located in the active site or the substrate access channel. Docking of progesterone into the P450 3A4 model demonstrated that the substrate bound in a 6β-orientation can interact with a number of active site residues, such as 114, 119, 301, 304, 305, 309, 370, 373, and 479, through hydrophobic interactions. The active site of the enzyme can also accommodate erythromycin, which, in addition to the residues listed for progesterone, also contacts residues 101, 104, 105, 214, 215, 217, 218, 374, and 478. The majority of 3A4 residues which interact with progesterone and/or erythromycin possess their equivalents in key residues of P450 2B enzymes, except for residues 297, 480 and 482, which do not contact either substrate in P450 3A4. The results from docking of progesterone and erythromycin into the enzyme model make it possible to pinpoint residues which may be important for 3A4 function and to target them for site-directed mutagenesis.


Life Sciences | 1997

Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450.

Grazyna D. Szklarz; James R. Halpert

In recent years, homology modeling has become an important tool to study cytochrome P450 function, especially in conjunction with experimental approaches such as site-directed mutagenesis. Molecular models of mammalian P450s can be constructed based on crystal structures of four bacterial enzymes, P450cam, P450 BM-3, P450terp and P450eryF, using molecular replacement or consensus methods. In a model built by molecular replacement, the coordinates are copied from those of a given template protein, while consensus methods utilize more then one protein as a template and are based on distance geometry calculations. The models can be used to identify or confirm key residues, evaluate enzyme-substrate interactions and explain changes in protein stability and/or regio- and stereospecificity of substrate oxidation upon residue substitution by site-directed mutagenesis. P450 models have also been utilized to analyze binding of inhibitors or activators, as well as alterations in inhibition and activation due to residue replacement.


Drug Metabolism and Disposition | 2008

Application of molecular modeling for prediction of substrate specificity in cytochrome P450 1A2 mutants.

Youbin Tu; Rahul S. Deshmukh; Meena Sivaneri; Grazyna D. Szklarz

Molecular dynamics (MD) simulations of 7-ethoxy- and 7-methoxyresorufin bound in the active site of cytochrome P450 (P450) 1A2 wild-type and various mutants were used to predict changes in substrate specificity of the mutants. A total of 26 multiple mutants representing all possible combinations of five key amino acid residues, which are different between P450 1A1 and 1A2, were examined. The resorufin substrates were docked in the active site of each enzyme in the productive binding orientation, and MD simulations were performed on the enzyme-substrate complex. Ensembles collected from MD trajectories were then scored on the basis of geometric parameters relating substrate position with respect to the activated oxoheme cofactor. The results showed a high correlation between the previous experimental data on P450 1A2 wild-type and single mutants with respect to the ratio between 7-ethoxyresorufin-O-deethylase (EROD) and 7-methoxyresorufin-O-demethylase (MROD) activities and the equivalent in silico “E/M scores” (the ratio of hits obtained with 7-ethoxyresorufin to those obtained with 7-methoxyresorufin). Moreover, this correlation served to establish linear regression models used to evaluate E/M scores of multiple P450 1A2 mutants. Seven mutants, all of them incorporating the L382V substitution, were predicted to shift specificity to that of P450 1A1. The predictions were then verified experimentally. The appropriate P450 1A2 multiple mutants were constructed by site-directed mutagenesis, expressed in Escherichia coli, and assayed for EROD and MROD activities. Of six mutants, five demonstrated an increased EROD/MROD ratio, confirming modeling predictions.


Drug Metabolism and Disposition | 2010

Significant Increase in Phenacetin Oxidation on L382V Substitution in Human Cytochrome P450 1A2

Qingbiao Huang; Grazyna D. Szklarz

Human CYP1A2 is an important drug-metabolizing enzyme, similar in sequence to CYP1A1 but with distinct substrate specificity. We have previously shown that residue 382 affected CYP1A1 and CYP1A2 specificities with alkoxyresorufins. To determine whether this residue is also important for the metabolism of other substrates, we have investigated phenacetin oxidation by single (T124S, T223N, V227G, N312L, and L382V) and multiple (L382V/T223N, L382V/N312L, L382V/T223N/N312L, and L382V/T124S/N312L) mutants of CYP1A2. The enzymes were expressed in Escherichia coli and purified. All the CYP1A2 mutants that contained the L382V substitution displayed much higher activities than the wild-type enzyme, with kcat values 3-fold higher, in contrast to other mutants, for which kcat decreased. Likewise, a significant increase in specificity, expressed as the kcat/Km ratio, was observed for the mutants containing the L382V substitution. The efficiency of coupling of reducing equivalents to acetaminophen formation was decreased for all the single mutants except L382V, for which the coupling increased. This effect was also observed with multiple CYP1A2 mutants containing the L382V substitution. Low activities of the four other single mutants were likely caused by dramatically increased uncoupling to water. In contrast, the increase in activity of the L382V-containing mutants resulted from decreased water formation. This finding is consistent with molecular dynamics results, which showed decreased phenacetin mobility leading to increased product formation. The results of these studies confirm the importance of residue 382 in CYP1A2-catalyzed oxidations and show that a single residue substitution can dramatically affect enzymatic activity.


Biochemistry | 1998

Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe.

Huifen Faye Wang; Dick R; Hequn Yin; Licad-Coles E; Deanna L. Kroetz; Grazyna D. Szklarz; Harlow G; Halpert; Maria Almira Correia


Biochemistry | 1997

Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis

You Ai He; You Qun He; Grazyna D. Szklarz; James R. Halpert


Biochemistry | 1995

Site-directed mutagenesis as a tool for molecular modeling of cytochrome P450 2B1.

Grazyna D. Szklarz; You Ai He; James R. Halpert


Archives of Biochemistry and Biophysics | 1996

Elucidation of Amino Acid Residues Critical for Unique Activities of Rabbit Cytochrome P450 2B5 Using Hybrid Enzymes and Reciprocal Site-Directed Mutagenesis with Rabbit Cytochrome P450 2B4

Grazyna D. Szklarz; You Qun He; Karen M. Kedzie; James R. Halpert; Vicki L. Burnett


Drug Metabolism and Disposition | 1998

Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy.

Grazyna D. Szklarz; James R. Halpert


Drug Metabolism and Disposition | 2003

Characterization of Substrate Binding to Cytochrome P450 1A1 Using Molecular Modeling and Kinetic Analyses: Case of Residue 382

Jianguo Liu; Spencer S. Ericksen; Dan Besspiata; Charles W. Fisher; Grazyna D. Szklarz

Collaboration


Dive into the Grazyna D. Szklarz's collaboration.

Top Co-Authors

Avatar

James R. Halpert

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

You Qun He

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

You Ai He

University of Arizona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Qingbiao Huang

West Virginia University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Youbin Tu

West Virginia University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge